COGT Overview
Upcoming Projects (COGT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (COGT)
-
Discussing the recent part 1b results from the SUMMIT trial evaluating bezuclastinib in iSM (indolent Systemic Mastocytosis) presented at AAAAI
Tickers: COGT, BPMC
Executed On: Mar 28, 2024 at 09:00 AM EDT -
A Second Opinion: Discussing the ASH 2023 data from Cogent's bezuclastinib (SUMMIT STUDY) and BluePrint's elenestinib (HARBOR study) for treating indolent systemic mastocytosis
Tickers: COGT, BPMC
Executed On: Dec 22, 2023 at 12:00 PM EST -
Discussing the ASH 2023 data from Cogent's bezuclastinib (SUMMIT STUDY) and BluePrint's elenestinib (HARBOR study) for treating indolent systemic mastocytosis
Tickers: COGT, BPMC
Executed On: Dec 20, 2023 at 01:00 PM EST -
Discussing C-Kit targeting for CSU (chronic spontaneous urticaria), PN (prurigo nodularis, EOE (eosinophilic esophagitis), aSM (advanced systemic mastocytosis), and iSM (indolent systemic mastocytosis)
Tickers: CLDX, JSPR, BPMC, COGT
Executed On: Sep 12, 2023 at 10:30 AM EDT -
Discussing the initial data for GIST therapies presented at ASCO, including Bezuclastinib in combination with Sunitinib in 2L from Cogent Biosciences THE-630 from Theseus Therapeutics
Tickers: COGT, THRX
Executed On: Jun 13, 2023 at 06:00 PM EDT -
Checking on the systemic mastocytosis landscape with a focus on the potential of Ayvakit (avapritinib), BLU-263, and Bezuclastinib (CGT9486/ PLX9486)
Tickers: BPMC, COGT
Executed On: Mar 31, 2022 at 12:00 PM EDT
Upcoming & Overdue Catalysts (COGT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (COGT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
